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CLINICAL GUIDELINE
Guideline for the Management of Chronic Obstructive
Pulmonary Disease (COPD): 2004 Revision
COPD Guideline Working Group of the South African Thoracic Society
Objective. To revise the South African Guideline for the
Management of Chronic Obstructive Pulmonary Disease
(COPD) in the light of new insights into the disease and the
value of new treatment approaches and drugs. New aspects
considered include:
• A growing awareness of the impact of COPD in South
Africa, and the urgent need for prevention strategies
• The role of concurrent exposures to domestic and
occupational atmospheric pollution, and previous lung
infections including tuberculosis 
• The need to consider as goals of treatment both prevention
of exacerbations and improvement of quality of life (health
status) of patients with COPD 
• The development of both long-acting beta2-agonist and
anticholinergic drugs for use in COPD
• Emerging evidence on a limited role for inhaled
corticosteroids in the treatment of COPD.
Recommendations. These include primary and secondary
prevention; early diagnosis; staging of severity; assessment of
reversibility with bronchodilator and, in some, responsiveness
to corticosteroids; use of bronchodilators and other forms of
treatment; rehabilitation; and treatment of complications.
Advice is provided on the management of acute exacerbations,
and the approach to air travel, prescribing long-term oxygen,
and lung surgery including lung volume reduction surgery.
Prevention, both primary and secondary, remains the most
cost-effective measure in the management of COPD, and
deserves more emphasis, particularly on the part of health
care professionals. Primary prevention involves reducing
public exposure to cigarette and other forms of smoke, and
reduction of atmospheric pollution, and secondary prevention
limits exposure and resultant progression in those with
established disease. Spirometry is essential for the diagnosis of
COPD and in staging severity. In addition, a new classification
of severity that considers other indices of functional
impairment is provided. Treatment involves a progression
from ‘as-needed’ bronchodilators, through the addition of
other more effective bronchodilators, usually in combination,
in more severe stages. The importance of assessing potential
reversibility in every patient with persistent symptoms, and of
the limited role of oral and inhaled corticosteroids (ICS), is
emphasised. These approaches also reduce exacerbations and
may result in cost savings and improved prognosis. A
practical low-cost approach to rehabilitation is proposed.
Options. Treatment recommendations are based on the
following: the recommendations of the Global Obstructive
Lung Disease (GOLD) initiative, which provides an evidence-
based comprehensive and up-to-date review of treatment
options; independent evaluation of the level of evidence in
support of some of the new treatment trends; and
consideration of factors that influence COPD management in
South Africa, including lung co-morbidity and drug
availability and cost.
Outcomes.   The use of bronchodilators is driven by the
presence of symptoms, but regular assessment of benefit,
based on objective criteria, is essential. Several forms of
treatment reduce exacerbations, the most effective of these is
smoking cessation.
Evidence.  Working group of clinicians and clinical researchers
following detailed literature review, particularly of studies
performed in South Africa, and the GOLD guidelines.
Benefits, harms and costs. The guideline pays particular
attention to cost-effectiveness in South Africa, and promotes
the initial use of less costly options. It rejects empirical use of
corticosteroids both oral and inhaled, and promotes smoking
cessation, and selection of treatment based on objective
evidence of benefit. It also rejects a nihilistic or punitive
approach, even in those who are unable to break the smoking
addiction.
Validation.  The COPD Working Group comprised
experienced pulmonologists representing all university
departments in South Africa and some from private practice.
All contributed to the development of the previous version of
the South African guideline, and attend international
meetings. One (JRJ) represents South Africa on the GOLD
Guideline Executive.
Guideline sponsor. The meeting of the Working Group of the
South African Thoracic Society was sponsored by an
unrestricted educational grant from Boehringer Ingelheim
(South Africa) (Pty) Ltd. 
S Afr Med J 2004; 94: 559-575.
Report compiled by: E D Bateman, C Feldman, J O’Brien, M Plit, J R Joubert
Other members of the COPD Guideline Working Group of the South African Thoracic Society: G M Ainslie, S Abdool-Gaffar, C Bolliger, A Foden, 
M Greenblatt, E Irusen, J Killian, U Lalloo, J Mpe, O Mzileni, W Otto, D Pansegrouw, R I Raine, G Richards, S Visser  
Corresponding author: Professor E D Bateman, University of Cape Town Lung Institute, PO Box 34560, Groote Schuur, 7937, Cape Town. Tel: (021) 406-6901,
fax (021) 406-6902, e-mail: ebateman@uctgsh1.uct.ac.za
560
July 2004, Vol. 94, No. 7  SAMJ
ORIGINAL ARTICLES
1. Management summary
Components of care 
1. Recognition of disease (early diagnosis and staging). The
patient presents with chronic breathlessness, wheezing
and/or cough. The diagnosis is confirmed by spirometry: An
FEV1/FVC% (ratio of forced expiratory volume in 1 second
to forced vital capacity) of less than 70% indicates airflow
obstruction, and FEV1 is an indicator of severity.
2. Smoking cessation to arrest disease progression.
3. Improvement of breathlessness through treatment of
airflow obstruction, based on grading of severity.
4. Improvement of quality of life (pulmonary
rehabilitation and education).
5. Prevention and treatment of exacerbations.
6. Prevention and treatment of complications.
Assessment of severity
Management plan based on the grade of severity
Stage 0 Stage 1 Stage 2 Stage 3
Grade of severity Normal, but at risk Mild Moderate Severe*
FEV1
(% of predicted value) > 80 79 - 60 59 - 40 < 40 
Dyspnoea/ functional Normal exercise Limits strenuous Limits activities Impairs activities
impairment tolerance activity performed at of daily living,
‘normal’ pace to virtual inactivity
6-Minute Walking Distance (m) Normal < 600 - 200  < 200  
(> 600)
Body mass index (kg/m2) > 25 ≤ 25 - 21 < 21
Stage of COPD Prevention Bronchodilators Other drugs Other measures
Stage 0 • Education
FEV1 ≥ 80% • Avoidance 
measures: smoking 
cessation
Stage 1 As above On demand inhaled 
FEV1 60 - 79% short-acting beta2-agonist 
or anticholinergic broncho-
dilator alone or combination 
inhaler or oral theophylline
Stage 2 As above Symptom-driven regular A trial of oral or
FEV1 40 - 59% use of inhaled short- or inhaled corticosteroid
long-acting bronchodilators, is indicated where
alone or in combination FEV1 is below 50%
with oral theophylline. predicted. If objective
Two or 3 might be needed benefit (in FEV1 and
with increasing severity. effort tolerance)
Long-acting beta2-agonists is found, or the
include formoterol and patient has frequent
salmeterol, and long-acting exacerbations of
anticholinergic, tiotropium COPD (3 or more
per year) consider 
maintenance inhaled 
corticosteroids, or, rarely, 
low-dose oral corticosteroid
Stage 3 As above As above As above
FEV1 < 40% 
Prevention of
exacerbations:
• Influenza         
vaccination annually
• Regular 
bronchodilators 
(with inhaled 
corticosteroids in a 
minority)
Rehabilitation:
• Education
• Exercise programme
• Psychological         
support
• Nutrition
• Domiciliary oxygen
• Treatment of cor
pulmonale
• Treat complications
and co-morbidity
*Also severe if any of the following are present: repeated hospitalisation for exacerbations, co-morbidity, right heart failure, PaO2 < 6.5kPa, age > 65 years, respiratory acidosis.
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2. Introduction
Chronic obstructive pulmonary disease (COPD) is an
important cause of death and disability in both developed and
developing countries.  It is becoming more common and
accounts for significant and increasing utilisation of health care
resources with attendant increases in health care expenditure.
Cigarette smoking remains the major cause of COPD, but in
Africa and Asia domestic biomass fuel use and tuberculosis are
important additional causes.  
3. Definitions
COPD is a disease state resulting predominantly from smoking
tobacco, and is characterised by airflow obstruction, which is
generally progressive and is only partially reversible. 
The diagnosis of chronic bronchitis applies to patients who,
in the absence of other recognised causes, e.g. bronchiectasis,
have a chronic productive cough for at least 3 months of the
year in 2 or more successive years. Emphysema is a
pathological diagnosis describing permanent abnormal
enlargement of the airspaces distal to the terminal bronchioles,
accompanied by destruction of alveolar walls. Most patients
with COPD have elements of both chronic bronchitis and
emphysema in varying degrees, but some may have one
without the other.
4. Epidemiology of COPD
COPD is often diagnosed late because patients lack symptoms
in the early stages of the disease despite the presence of
moderate decreases in pulmonary function. The primary risk
factor for COPD is cigarette smoking. However in South Africa,
important contributory factors are tuberculosis, industrial and
mining dust exposures, and domestic use of  biomass fuels.3,4
As a result of these additional factors, the prevalence of COPD
is higher in poorer communities (Table I). It is not yet clear
what impact HIV infection and its attendant pulmonary
complications have on the pathogenesis and prevalence of
COPD in South Africa.
Estimates of the global all-age incidence of COPD are that it
affects 9/1 000 males and 7.3/1 000 females. It seldom presents
clinically before the 5th decade, but incidence increases in
successive decades and up to 50% of smokers over the age of
65 years are affected.5 Incidence also varies widely between
different regions and countries of the world, according to local
cigarette smoking habits and domestic and socio-economic
circumstances. It is more common in males than females, but
morbidity among women has increased sharply in many
countries, in parallel with an increase in the number of women
smokers. Patients with COPD have a more rapid age-related
decline in FEV1 than normal subjects. This accelerated decline
is slowed by smoking cessation. Recurrent infective exacerba-
tions may also accelerate the rate of disease progression.
Morbidity and mortality increases with severity of disease, age
and co-morbidity.6 The 2-year mortality is 20% in patients with
an FEV1 of 30 - 39%, and 40% in those with an FEV1 of less than
30% of predicted. 7
5. Objectives
The purpose of this guideline is to improve the care of patients
with COPD in all sectors of care in South Africa. It includes an
action plan for the recognition and appropriate treatment of
this common condition, but is not intended to be prescriptive.
The goals of management are listed below (Table II).
6. Goals of management
6.1.  Recognition of disease (early diagnosis and
staging of severity)
The diagnosis of COPD should be considered in any patient
with chronic dyspnoea and/or chronic cough (with or without
sputum production), a smoking history of more than 10 pack-
years, and/or other risk factors for COPD (Table I), particularly
if there is no other apparent cause for these symptoms (e.g.
cardiac failure). One pack-year equals 20 cigarettes per day, one
joint of cannabis per day, or 15 g of pipe tobacco per day, for 1
year. In South Africa, more than one risk factor is commonly
found. 
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Table I. Risk factors for the development of COPD in South
Africa
Cigarette smoking
Pulmonary tuberculosis
Harmful exposures in mining and industry
Domestic use of biomass fuels
Smoking of marijuana and ‘recreational drugs’, e.g.
methaqualone
Alpha-1 protease inhibitor deficiency (rare)
Childhood lung infections
Table II. Goals of management of patients with COPD
1.  Recognition of disease (early diagnosis and staging)
2.  Smoking cessation to arrest disease progression
3.  Improvement of breathlessness (treatment of airflow
obstruction)
4.  Improvement of quality of life (pulmonary rehabilitation
and education)
5.  Prevention and treatment of exacerbations
6.  Prevention and treatment of complications
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Correct diagnosis, and in particular, the differentiation of
COPD from asthma is important to ensure correct treatment.
Clinical features that assist in the diagnosis of each are outlined
in Table III.  The severity of COPD is defined on the basis of
spirometry and various clinical features (Table IV). 
6.1.1 Spirometry
Spirometry is essential for the detection, assessment and
management of  patients with COPD and must be performed
by adequately trained persons using a spirometer of approved
standard and quality that is calibrated regularly.8
Measurements used in the diagnosis of COPD are  FEV1 after
bronchodilator use and the ratio of FEV1 to FVC (FEV1/FVC%).
6.1.1.1 Detection of airflow obstruction
The presence of an FEV1/FVC ratio of less than 70% confirms
the presence of airflow obstruction. In these circumstances, the
FEV1 is usually reduced (less than 80% of predicted value), and
is used as a measure of severity. Most patients with
symptomatic COPD have a reduced FEV1, but many patients
with significantly reduced FEV1 have no symptoms. An FEV1 of
< 80% of predicted after four inhalations of a short-acting beta2-
agonist in patients at risk, regardless of whether or not they
have symptoms, suggests a diagnosis of COPD.
A slow or ‘relaxed’ vital capacity (SVC), that is, a vital
capacity performed as a maximal but unhurried manoeuvre,
frequently provides a larger value than the forced manoeuvre
Table III.  Distinguishing features of COPD and asthma
Features suggesting a diagnosis of  COPD
• Persistent unremitting dyspnoea, wheeze and productive cough despite treatment
• A long history of smoking
• Slow progression
• Hyperinflation and abnormal spirometry that persists during a stable phase of the disease
• Cyanosis
Features that suggest the presence of asthma 
• Young age of onset
• Presence of atopy and/or allergic rhinitis
• Diurnal and day-to-day variation and seasonal variability
• Marked improvement after a bronchodilator and/or a 2-week trial of systemic steroids
Additional considerations in the diagnosis of asthma and COPD 
• Asthma and COPD may coexist and distinguishing them may be difficult
• Breathlessness occurs late in COPD
• Asthmatics who smoke may have an accelerated decline in lung function
• Industrial exposure (e.g. to silica dust) and previous tuberculosis are also associated with the development of fixed airflow obstruction
Table IV.  Assessment of severity 
Stage 0 Stage 1 Stage 2 Stage 3
Grade of severity Normal, but at risk Mild Moderate Severe*
FEV1
(% of predicted value) > 80 79 - 60 59 - 40 < 40
Dysponea/functional Normal exercise Limits strenuous Limits activities Impairs activities of 
impairment tolerance activity performed at daily living, to
‘normal’ pace virtual inactivity
6-MWD† Normal
(m) (> 600) < 600 - 200 < 200 
BMI‡
(kg/m2) > 25 ≤ 25 - 21 <  21
*Also severe if any of the following are present: repeated hospitalisation for exacerbations, co-morbidity, right heart failure, PaO2 < 6.5 kPa, age > 65 years, respiratory acidosis.†6-MWD = distance in metres walked in 6 minutes. Normal value in health > 600 m; moderate impairment < 300 m; severe impairment < 200 m. A change of 10% is considered
clinically significant (see Annexure A).
‡BMI = body mass index, calculated as follows: mass in kg divided by height in m2. A change in BMI of 1 kg/m2 is considered significant.
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in patients with COPD. Consequently, the FEV1 expressed as a
ratio of SVC (FEV1/SVC%) improves the sensitivity of
spirometry. Technical difficulties in assuring the quality and
reproducibility of this manoeuvre limit its use. It is used by
pulmonologists and those with suitable technical training.
6.1.1.2 Assessment of severity of airflow obstruction
To establish the severity of COPD, FEV1 is expressed as a
percentage of predicted values. The European Community for
Steel and Coal (ECSC) predicted values (based on surveys
performed in Europe) are recommended for routine use in
South Africa.9 It must however be noted that ethnic differences
(amounting to approximately 12% lower values for FVC in
Africans or African Americans) have been demonstrated in
some series, and a correction factor (multiplication of the
spirometric value by 0.9) might in some circumstances be
advisable.
Measurement of peak expiratory flow (PEF), while helpful in
suspected asthma, is not an appropriate test for diagnosing and
evaluating the severity of COPD and does not distinguish
obstructive from restrictive lung disease. It has limited use for
patients who require monitoring to detect exacerbations, but is
not used for assessing response to treatment.
6.1.1.3 Assessment of reversibility with short-acting
bronchodilators
Spirometry should be performed before and 20 minutes after
four puffs of a short-acting beta2-agonist bronchodilator (e.g.
salbutamol, fenoterol or terbutaline). An improvement in FEV1
≥ 12% from baseline and > 200 ml is considered to indicate a
significant reversible component. Although reversibility of this
magnitude is more common in asthma, it also occurs in a
significant proportion of patients with COPD. However, in
general, the larger the improvement the greater the likelihood
that the diagnosis is asthma. Asthma is confirmed if the post-
bronchodilator FEV1 exceeds 80% of predicted.
A trial of systemic (oral) corticosteroids given for 14 days
(Table V) forms part of the diagnostic assessment and is
recommended in most symptomatic patients with severe
airflow obstruction (FEV1 < 50% of predicted) and particularly
when asthma is suspected. A post-bronchodilator FEV1 at the
end of the steroid trial of > 80% of predicted confirms asthma.
Partial improvement to less than 80% of predicted is more
problematic to interpret, and suggests fixed airflow obstruction
and a diagnosis of COPD. Partial improvement does not
predict responsiveness to inhaled corticosteroids, but may be
considered an indication for a strictly supervised trial of
inhaled corticosteroids (see assessment of responsiveness to
corticosteroids).
6.1.2 Assessment of severity of COPD 
The assessment of severity of COPD is not based on
spirometric measures alone, but on a combination of FEV1 and
several clinical indicators including severity of dyspnoea,
functional impairment, 6-minute walking distance (6-MWD)
and body mass index (BMI).10 Grading of severity is used for
prognostication and for selecting treatment. Details of the
grades of severity are provided in Table IV.
6.1.3 Progression of disease and prognosis
The FEV1 is a static measurement and only predicts prognosis
when severely reduced (< 40% predicted).6 Dyspnoea and
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Table V. Trial of responsiveness to corticosteroids 
• Indications
1. Patients suspected to have COPD who have significant but partial reversibility with short-acting beta2-agonists (to aid diagnosis).
2. All patients with moderate or severe COPD (to aid selection of treatment) 
• Dose: Prednisone 40 mg or methylprednisolone 30 mg once daily for 14 days, or inhaled corticosteroid equivalent to 800 µg
budesonide daily for 6 weeks (400 µg twice daily) 
• Assessment of response before and after completion of treatment course
1. Detailed history of effort tolerance (with examples of activities)  
2. Measurement of FEV1
3. 6-MWD
• Interpretation of results 
1. Improvement of FEV1 to ≥ 80% of predicted. Diagnosis is asthma . . . treat as asthma 
2. Partial improvement: Clear evidence of less dyspnoea/functional impairment and/or improvement of > 12% (and at least 200 ml) 
of  baseline FEV1, or an improvement of > 10% in the 6-MWD  — add inhaled corticosteroids to treatment on a trial basis for a 
(further) 6-week period  
3. Little or no improvement (i.e. less than in 2): Reserve corticosteroids for acute exacerbations of COPD, but do not use as 
maintenance treatment 
• A short trial of corticosteroids will not reactivate tuberculosis. If  active tuberculosis is suspected and in cases where long-term
steroid therapy is planned, an initial chest radiograph is advised 
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Table VI.  Integrated management plan for COPD 
Stage of COPD Prevention Bronchodilators Other drugs Other measures
Stage 0 Education
FEV1 ≥ 80% Avoidance measures:
smoking cessation
Stage 1 As above On demand inhaled 
FEV1 short-acting beta2-agonist
60 - 79% or anticholinergic broncho-
dilator alone or combination
inhaler or oral theophylline
Stage 2 As above Regular use of inhaled short-or 
FEV1 long-acting bronchodilator, alone 
40 - 59% or in combination +/- oral 
theophylline. Two or 3 might be 
needed with increasing severity. 
Long-acting beta2-agonists include
formoterol and salmeterol, and
long-acting anticholinergic, 
tiotropium 
Stage 3 As above As above As above
FEV1 < 40%
A trial of oral or
inhaled corticosteroid
may be considered
where FEV1 is below
50% of predicted and if
objective benefit (in
FEV1 and effort
tolerance) is found, or
the patient has
frequent exacerbations
of COPD (3 or more
per year) (See notes on
corticosteroids)
Prevention of
exacerbations:
• Influenza vac-
cination annually
• Regular broncho-
dilators (with inhaled
corticosteroids in a
minority)
Rehabilitation:
• Education
• Exercise programme
• Psychological
support
• Nutrition
• Domiciliary oxygen
• Treatment of cor
pulmonale
• Treat complications
and co-morbidity
functional impairment are linked because grade of dyspnoea is
allocated according to the activities that provoke it, and
dyspnoea is the symptom that most commonly limits
activities.11 Together, dyspnoea and functional impairment
predict prognosis. The 6-MWD is another more objective and
reproducible measure of functional impairment and can be
used to follow the progression of disease.  In the absence of
other cause of weight loss, a decline in BMI is associated with
advanced disease. A value of < 21 kg/m2 is associated with a
50% 5-year mortality.10
FEV1 declines slowly at a rate of 50 - 60 ml per year.12 Rapid
symptomatic deterioration may result from the development of
complications, such as pulmonary thrombo-embolism, right
heart failure and ischaemic heart disease with left ventricular
failure.
6.1.4 Chest radiography 
The chest radiograph on its own is not diagnostic, and has a
high false-positive rate. Moreover, a normal chest radiograph
does not exclude the diagnosis of COPD. A chest radiograph is
therefore not essential for the diagnosis unless additional
pathologies are suspected. The presence on chest radiograph of
structural disease such as bullae and scarring from previous
tuberculosis increases the likelihood that airflow limitation, if
present, will be irreversible.
6.1.5 An integrated management plan for COPD
An integrated management plan for the management of COPD,
based on the grades of severity, is provided in Table VI.
• Stage 0 — normal, but at risk (FEV1 ≥ 80% of predicted).
Patients are asymptomatic, but are exposed. The strategy is
to prevent further damage. Smoking and other risk factors
must be stopped and avoided. 
• Stage 1 — mild COPD (FEV1 60 - 79%  of predicted).
Patients may be asymptomatic; treatment is prevention of
further exposure (as above), and of progression factors, e.g.
exacerbations. Bronchodilators: short-acting inhaled beta2-
agonist or anticholinergic, or a combination inhaler taken as
needed according to symptoms. Oral theophylline can be
added if symptoms are more regular or persistent.
• Stage 2  — moderate COPD  (FEV1 40 - 59% of predicted).
Symptoms are more persistent and limit activities; treatment
ORIGINAL ARTICLES
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as above, plus one or more bronchodilators taken regularly.
Theophylline may be added. A long-acting bronchodilator
may be considered (beta2-agonist or anticholinergic). Inhaled
corticosteroids, alone or in combination, should be used only
in selected cases. Rehabilitation is important.
• Stage 3  — severe COPD  (FEV1 < 40% of predicted).
Symptoms are persistent and limit even the lightest daily
activities such as bathing, dressing and walking a few
metres; treatment as for stage 2. Use of a combination of
bronchodilators, taken regularly, is advised. A trial of
corticosteroids is recommended and either oral or inhaled
maintenance treatment may be considered. Prevention of
exacerbations is essential. Treatment of chronic respiratory
failure (hypoxaemia) with domiciliary oxygen, cor
pulmonale and other complications may be required.
Rehabilitation is essential.
6.2 Smoking cessation (primary and secondary
prevention)
Smoking cessation is the only measure that has been shown to
slow progression of COPD, and is one of the most cost-effective
interventions in health care. All smokers, and particularly those
with COPD, must be encouraged to stop smoking, and all
health care workers should be familiar with and promote
smoking cessation among their patients.
Avoidance of occupational and atmospheric pollution,
including passive or ‘side-stream’ tobacco smoke exposure is
desirable for all, but particularly important for susceptible
persons, namely pregnant women, infants and children, and
persons with COPD, especially those with alpha-1-anti-
protease deficiency.
The addictive nature of nicotine is attributable to its unique
physiological effects on the central nervous system, i.e. both
stimulation and relaxation and improved concentration and
vigilance. Appetite suppression aiding weight control is an
additional attraction for many. Together, these effects persuade
many to continue smoking in the face of compelling evidence
of its harmful effects.
Benefits of smoking cessation in patients with COPD.
Although much lung damage caused by smoking is
irreversible, all patients must be encouraged to stop smoking,
regardless of the severity of their disease. Advantages of
cessation include:
1.  Slowing of the rate of decline of lung function to that of
normal ageing. A small improvement in spirometry occurs in
some.
2. Improved oxygen transport in blood, through reductions
in carboxyhaemoglobin, and blood viscosity.
3. Reduced tendency to thrombosis.
4. Improvements in appetite, body mass, muscle strength
and exercise tolerance.
5. Possible improved efficacy of some classes of drugs used
in COPD.
6. Delayed development of respiratory failure and cor
pulmonale.
6.2.1 Smoking cessation programmes 
The plethora of smoking cessation methods advertised in the
popular and medical press reflects the poor efficacy of most in
overcoming the addictive effects of nicotine. Many are
behavioural in approach, but some are pharmacological, and
involve gradual weaning from nicotine through nicotine
replacement, with or without mood modifiers to counteract the
negative effects of withdrawal. Many interventions show
impressive short-term results, but long-term abstinence
(defined as cessation without relapse that lasts for 12 months)
occurs in fewer than 30% of patients (for most methods only 
15 - 20%). Factors associated with poor success include
multiple previous attempts, heavy smoking  and relapse within
the first 2 weeks.
6.2.2 Features that contribute to a successful programme
1. An initial in-depth interview to discuss the patient’s smoking
habits and  previous quit attempts and that provides
information and advice on cigarette brands (including tar and
nicotine content), withdrawal symptoms and coping strategies.
Cessation advised by a doctor, particularly if repeated on
several occasions, has been shown to be more effective than
advice offered by other health care professionals. Several
medical aids reimburse smoking cessation counselling.
2. Abrupt cessation rather than gradual smoking reduction,
with agreement on a ‘quit date’ and provision of support for
adherence to the commitment (by phone call).
3. Reinforcement and follow-up. Some programmes
recommend a schedule of follow-up visits, e.g in weeks 1, 2, 4,
8, 12, 16, 20, 26 and 52, but support provided during usual
visits to clinic or rooms is also effective. 
4. Nicotine replacement is advised for patients who are
unsure of their ability to stop, where there are signs of severe
addiction, and/or if severe withdrawal symptoms have been
experienced during a previous attempt. Options are a
sublingual spray, inhaler, gum and patches. Clinicians should
be familiar with the advantages and disadvantages of each
method, potential medical complications with their use,
recommended dosing schedules, and limits to their use.13
5. Additional pharmacological support: use of bupropion
improves the quit rate. Nortriptyline is of limited benefit.
Buspirone and clonidine are ineffective.
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Clinical trials examining the efficacy of hypnosis and acupuncture
have shown no additional benefit of these treatments.
6.2.3 Awareness programmes
Awareness programmes serve to protect the public from
cigarette smoking and other harmful exposures, with the
particular aim of protecting susceptible individuals (children,
asthmatics and individuals with impaired lung function).
6.2.4 Other preventive measures
These include practical measures to avoid exposure to cold and
influenza at home and work and include annual influenza and
5-yearly pneumococcal vaccination. 
6.3 Improvement of breathlessness (treatment of
airflow obstruction)
6.3.1 Mild disease
If the patient is breathless, treat with one of the following
bronchodilators (see notes on bronchodilators).
•  Beta2-agonist inhaled (e.g. salbutamol, fenoterol and
terbutaline, approximately 6-hourly as needed,
administered via metered dose inhaler (MDI) (dose 2 puffs)
or dry powder inhalation device (DPI) (single dose).
OR
•  Anticholinergic inhaled (e.g. ipratropium —  adminis-
tration and dose as above).
OR
•  Combination MDI containing short-acting anticholinergic
(e.g. ipratropium and beta2-agonist — administration and
dose as above).
OR
•  Regular oral slow-release theophylline (200 - 400 mg twice
daily or 400 - 800 mg at night as a daily dose).
6.3.2 Moderate and severe disease
First consider a trial of oral or inhaled corticosteroids (see
below). This forms part of the diagnostic assessment and is an
indicator of likely responsiveness to therapy. It also establishes
a target lung function for bronchodilator treatment and should
be performed unless a medical contraindication exists.  Patients
should be in a stable phase. 
Include combinations of bronchodilators (usually at least 2
with different modes of action and combined effect). One or
more of the following combinations should be considered:
•  Regular beta2-agonist and anticholinergic either from a
single combination MDI or from separate MDI (or DPI)
devices: usually 2 puffs (up to 4 in severe cases)
approximately 6-hourly as needed.
OR
•  Regular long-acting beta2-agonist (e.g. salmeterol or
formoterol 12-hourly) with short-acting inhaled
bronchodilator ‘rescue’ as needed.
OR
• Regular long-acting inhaled anticholinergic (e.g.
tiotropium) with short-acting inhaled beta2-agonist ‘rescue’
as needed.
• Any of the above may be combined with regular oral slow-
release theophylline given either once or twice daily (200 -
400 mg twice daily or 400 - 800 mg daily, take at night).
6.3.3 Notes on bronchodilators
6.3.3.1 General principles 
• Most patients with COPD have a degree of reversible
airways obstruction and display hyperresponsiveness on
bronchial challenge.
• Most patients respond with partial improvement in FEV1. In
some there are also improvements in FVC, inspiratory
capacity and SVC and reduction in gas trapping.
• In many patients there is a partial relief of symptoms,
improved quality of life and a reduction in the frequency
and/or severity of exacerbations. The magnitude of these
benefits is usually less than in asthma.
• Bronchodilators do not alter the progressive decline in FEV1.
• Even patients who do not demonstrate a bronchodilator
response on spirometric testing should be given a trial of
bronchodilator treatment as breathlessness may be
improved by a number of mechanisms.
• The main classes of bronchodilators are beta2-agonists,
anticholinergics and theophylline.
• The development of long-acting bronchodilators (beta2-
agonists and anticholinergics) represents a significant
advance in the treatment of COPD.
• Bronchodilators may be most effective when used in
combinations that exploit their different mechanisms of
action.
• A measured FEV1 response to a single dose of
bronchodilator does not predict long-term response.
• In all but mild COPD their use must be regular and long-
term rather than ‘as needed’ as in asthma.
• The addition of more bronchodilators to the treatment
regimen in individual patients is ‘symptom-driven’, that is,
bronchodilators are added until maximal relief of
breathlessness and/or improvement in effort tolerance and
quality of life is achieved or dose is limited by side-effects.
• Because individual patients respond differently to the
various classes of bronchodilators, and responses cannot be
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reliably predicted, a process of trial and review is
recommended to establish which drugs in combination
provide the best result in each patient. This usually takes
several visits over months, but ensures that the most cost-
effective drugs and combinations are used.
6.3.3.2 Delivery devices for bronchodilators 
• Inhaled bronchodilators are preferred over oral agents as
they: 
• are generally more effective
• are more conveniently titrated
• have fewer side-effects.
• The pressurised metered dose inhaler (pMDI) operated by
the patient using the ‘push-and-breathe’ method is the most
widely accepted and used method of delivery of inhaled
bronchodilators (and corticosteroids) and at lowest cost.
• Up to 40% of patients, and possibly more in the elderly and
those with severe disease or physical limitations such as
arthritis, have difficulty using these devices, particularly co-
ordinating actuation with inspiration. Consequently they
derive little or even no benefit in spite of adherence to
dosing schedules. Since this is also the group of patients in
whom the greater systemic effects of oral bronchodilator use
are most significant (tachycardia, arrhythmias, tremor and
gastro-intestinal effects), other methods of delivering
inhaled drugs should be considered.
• Spacer devices. These are widely used for delivery of
inhaled corticosteroids because they reduce oral deposition
of drug. However, their size makes them unsuitable for
bronchodilators, which in general need to be carried about
during the day for frequent use, and mastery of the
technique of use is a problem for some.
• Breath-activated pMDIs and powder devices overcome the
above problems but are more costly.
• Nebulisers are an option for delivering high doses of
bronchodilator in patients with advanced disease, poor
inhalation technique and/or during exacerbations.
Nebulised ipratropium plus beta2-agonists can be used 3 or
more times daily. In general, nebulisers tend to be overused
in COPD, resulting in unnecessary expense. Patients
requiring nebuliser therapy should, where possible, be
assessed by a specialist for review of their treatment.
• It is vital to ensure that the individual is able to use the
delivery device that is prescribed. This should be checked at
regular intervals during follow-up visits.
6.3.3.3 Anticholinergics
• Bronchodilatation achieved with anticholinergics results
from inhibition of muscarinic receptors in the lung, thereby
reducing airway tone, and relieving bronchospasm. The
location and distribution of muscarinic receptors in the lung
differs from that of beta2-receptors, and their functional role
may be more important in the elderly and in smokers.  This
might account for their apparent superior efficacy over
other classes in the elderly and smokers, observed in some
studies.
• They have a slower onset of action than rapid-acting beta2-
agonists (± 40 minutes to peak effects versus 10 - 20
minutes) but are effective for longer (6 hours for
ipratropium bromide, and more than 24 hours for
tiotropium).
• Efficacy is dose-dependent, and the dose of ipratropium can
be safely increased to obtain a better effect.
• Their use is associated with fewer side-effects, especially in
COPD and the elderly, and unlike beta2-agonists which may
be associated with tachycardia, palpitations, tendency to
cause hypoxaemia and tachyphylaxis.  A small proportion
of patients experience dryness of the mouth. No impairment
of mucociliary clearance has been reported. Significant
urinary or pupillary effects are uncommon, even in high
doses and in the elderly.
• They may be safely combined with beta2-agonists.
• Long-acting anticholinergic (tiotropium). Tiotropium is an
anticholinergic that causes prolonged and selective blockade
of human M1 and M3 receptors. Its clinical effect in patients
with moderate and severe disease is superior to ipratropium
without increasing side-effects. Improvement in lung
function is greater and sustained over 24 hours, permitting
once-daily dosing. It is at least as effective as long-acting
beta2-agonists and is superior for certain end-points,
including duration of action. It is available only in powder
form via a Handihaler device.
6.3.3.4 Beta2-agonists
• Short-acting beta2-agonists. These have a rapid onset of
action and achieve similar effects to anticholinergics. They
may be used regularly and as monotherapy. Examples
include salbutamol, fenoterol and  terbutaline.
• Long-acting beta2-agonists. The group includes salmeterol
(given in a dose of 50 µg twice daily) and formoterol (in a
dose of 9 or 18 µg twice day). Regular use of doses higher
than these is not recommended. Combining long-acting
beta2-agonists with inhaled steroids may provide additional
benefits in terms of symptom control and reduction in
exacerbations. However this combination should not  be
considered first-line therapy.
6.3.3.5 Oral theophylline
• Theophylline has less of a bronchodilator effect than
anticholinergics and beta2-agonists but has several
additional therapeutic benefits including a measurable
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effect on markers of airway inflammation in COPD. Other
benefits are low cost, and oral route of administration,
which is preferred by some patients and may improve
compliance. Disadvantages are toxicity (particularly in the
elderly), drug interactions and variable metabolism. 
• They are better tolerated if started at a low dose (half or one
tablet daily for a week) and then increased to the full
therapeutic dose, and given after a meal. Initial gastro-
intestinal side-effects like anorexia, nausea and change in
bowel habit may improve with continued use.
• Sustained-release tablets (both twice- or once-daily
formulations are available) are recommended for
maintenance treatment.
• Theophylline can be safely used in combination with other
classes of bronchodilator.
• Dosage: oral slow-release theophylline, 200 - 400 mg twice a
day or 400 - 800 mg at night.  Recommended doses should
not be exceeded without monitoring blood levels.
• A scheme for adjusting doses to certain categories of
patients is as follows: (i) smokers and patients on phenytoin
therapy — increase dose by one-third; and (ii) patients with
congestive cardiac failure or liver disease, the elderly, and
those on most macrolide antibiotics, ciprofloxacin or
cimetidine — decrease the dose by one-third.
• Combination tablets containing theophylline and other
bronchodilators or sedatives are not recommended. 
6.3.3.6 Comparison of different combinations of
bronchodilators 
A step-wise increase in inhaled and oral agents with the final
combination determined by the maximum functional response
achieved in each individual should be followed.  This may
include combinations of short-acting beta2-agonist and short-
acting anticholinergic, long-acting beta2-agonist with short-
acting anticholinergic, or long-acting anticholinergic with a
short-acting beta2-agonist. The potential benefit of combining a
long-acting beta2-agonist with tiotropium has not been studied,
and is an expensive option. Although both the long-acting
beta2-agonists and anticholinergics are more expensive than
their short-acting counterparts they achieve and maintain a
higher level of clinical benefit (less dyspnoea, improved effort
tolerance, improved FEV1 and fewer exacerbations). Owing to
their cost they should not be used as first-line therapy. They are
recommended for patients with severe or symptomatic
moderate grades of COPD. Consideration should be given to
stopping them if no symptomatic benefit is evident. Oral
theophylline may be added to any combination of inhaled
treatment. The effects of these and other drug combinations on
survival in patients with severe COPD has not been confirmed,
but long-term studies are underway. 
6.3.4 Notes on corticosteroids
6.3.4.1 Trial of corticosteroids: Assessment of responsiveness to
corticosteroids (systemic or inhaled)
A trial of oral corticosteroids is indicated in patients with
significant persistent breathlessness as an aid to distinguishing
COPD from asthma and deciding on the need for continued
treatment with inhaled or even oral corticosteroids. A 6-week
trial of high-dose inhaled corticosteroids is an alternative for
this purpose (Table  VI). This must be monitored with
spirometry. Another objective test of response is the Six Minute
Walk Distance (6-MWD) (see Annexure A).
6.3.4.2 Chronic oral corticosteroids
Chronic oral corticosteroid use improves symptoms and lung
function in a small proportion of patients, but because of side-
effects should be used with caution, and only when there is
objective evidence of improvement in patients tested during a
period of relative stability. When initiated, regular attempts
should be made to reduce treatment to the lowest dose that is
not associated with acute exacerbations or worsening
breathlessness, and a dose of greater than 7.5 mg of prednisone
(or equivalent) is seldom beneficial or indicated. Sustained use,
and repeated short high-dose courses are associated with
severe side-effects, particularly in the elderly. The development
of muscle weakness and osteoporosis with vertebral collapse is
common. Both further limit activity and accelerate functional
decline. Where continued use is indicated, a switch to inhaled
corticosteroids (equivalent to 400 mg budesonide twice daily)
should be attempted, starting with a 6-week trial period (see
above).
6.3.4.3 Inhaled corticosteroids
The use of inhaled corticosteroids in COPD remains contro-
versial. Although there is evidence of airway inflammation in
COPD, the benefits of long-term preventive inhaled
corticosteroid treatment, as recommended for asthma, are
limited. In steroid-withdrawal trials and in prospective trials
involving their addition to bronchodilator therapy, their use
has been associated with the reduction of frequency and/or
severity of acute exacerbations of COPD, and symptomatic
improvements in a minority of subjects. Initial results of trials
in combination with long-acting beta2-agonists suggest some
additive benefit.
6.3.5  Mucolytics and mucokinetic agents
Expectoration of tenacious sputum is a distressing symptom.
Mucolytics, mucokinetic drugs and cough syrups (oral and
inhaled) have not been shown to be effective, and are not
recommended.  Regular dosing with oral acetylcysteine has
provided limited benefit in some but not all studies.  
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6.3.6 Chest physiotherapy
An ineffective cough may be improved by instruction in the
‘huff technique’ of coughing and active cycle of breathing.
Percussion and vibration therapy does not form part of routine
management in stable patients.
The physiotherapist has an important role to play in
directing the conditioning (exercise) programme and in
advising on breathing and coughing techniques.
6.3.7 Other anti-asthma drugs
Other anti-asthma drugs, e.g. sodium cromoglycate, ketotifen
and nedocromil sodium, are of no value in COPD.
6.3.8 Venesection
Increased haematocrit causes aggravation of cardiac failure,
increased ventilation/perfusion abnormality and an increased
incidence of thrombotic episodes. When the haematocrit is 
> 0.55 consider repeated therapeutic venesection.
6.3.9 Other procedures and techniques
‘Therapeutic’ bronchoscopy and pulmonary lavage have no
place in the routine management of COPD.
6.4 Improving quality of life (pulmonary
rehabilitation and education)
Improvement in health status in COPD is recognised as one of
the most important goals of therapy, since it reflects the
patient’s perspective and may be more clinically relevant than
a physiological endpoint like FEV1. Health status
questionnaires are now routinely used in studies of drugs and
other treatment modalities. Several drug combinations
recommended above are also associated with sustained benefit
to quality of life and may slow the rate of deterioration. Long-
term domiciliary oxygen therapy also improves health status
and if used appropriately on selected patients, prolongs life.  
Rehabilitation involves a multidisciplinary programme of
physiotherapy, muscle training, nutritional support,
psychotherapy and education.  Rehabilitation programmes
improve exercise tolerance and health status (quality of life),
and should be offered in specialised centres. 
6.4.1 Education 
Education involves the following advice (preferably written):
• Benefits and techniques of smoking cessation
• Pathophysiology of disease
• Prognosis
• Drug treatment and side-effects of drugs
• A crisis plan for attacks of severe breathlessness or infection
— who to contact and how to cope
• Physiotherapy techniques
• Goals of exercise programmes
• Use of oxygen.
6.4.2 Physical conditioning
All patients, regardless of age, who are adequately motivated,
should be included in rehabilitation programmes. In its
simplest form physical conditioning should include a graded
programme of upper and lower limb exercise, e.g. free-range
walking. Cycling and treadmill walking are useful alternatives.
Hypoxic patients should be exercised with caution. Supervised
programmes designed to improve both muscle endurance and
strength, particularly in the muscles of the extremities and
thorax, result in improvements in the 6-MWT, reduced
dyspnoea and improved quality of life, and recovery after
exacerbations may be more rapid.
Initial exercise programmes are individualised according to
the patient’s disease severity and mobility. In the first weeks
the duration and intensity of exercises are increased to a level
that is sustainable for a total of 15 - 45 minutes per session.
Four or more sessions per week are recommended, at least
some of them under supervision. Such programmes last 6 - 8
weeks, but patients must be encouraged to continue the
exercise prescription indefinitely, or the benefit will be
temporary.
For more severe disease, breathing exercises, e.g. pursed-lip
breathing to improve airflow during expiration, ‘diaphragmatic
breathing’ and relaxation techniques may be of benefit. Energy
conservation measures for the severely breathless include
synchronised breathing, avoidance of breath-holding, arm
support during activities such as shaving, devices to aid
towelling and bathing, etc.
6.4.3 Psychological support
This involves group and family support and advice to the
family from the practitioner and other caregivers.
6.4.4 Nutrition
Obesity and loss of body mass are both common features of
COPD. Obese patients should be advised to lose weight.
Under-nutrition is associated with respiratory muscle
dysfunction and increased mortality. Weight gain in advanced
COPD is generally difficult to achieve. Simple advice to take
frequent small meals and not have large meals shortly before
retiring may improve nutrition and limit the dyspnoea
associated with eating. Anabolic steroids improve body mass in
patients with weight loss, but do not have a sustained
beneficial effect on respiratory muscle strength or effort
tolerance.
569
July 2004, Vol. 94, No. 7  SAMJ
570
July 2004, Vol. 94, No. 7  SAMJ
ORIGINAL ARTICLES
6.4.5  Long-term domiciliary oxygen therapy (LTDOT)
The purpose of oxygen therapy is to correct hypoxaemia,
thereby preventing the effects of the latter on various organ
systems. The full benefit is therefore only evident in patients
with persistent hypoxaemia. In such patients it has been shown
to reduce the complications of respiratory and right heart
failure and to improve survival.
6.4.5.1 Indications for LTDOT
• Non-smokers with stable, severe COPD (usually but not
exclusively with an FEV1 of less than 1.5 l and
FEV1/FVC < 70%)
• Arterial hypoxaemia (PaO2 less than 7.3 kPa or 55 mmHg)
or oxygen saturation < 90% at rest 
• With or without hypercapnia (PaCO2 greater than 6.0 kPa or
45 mmHg)
• With or without oedema.
Severe airflow obstruction (low FEV1 and FEV1/FVC) must
be confirmed since LTDOT is not of proven benefit in other
forms of disease. Before prescribing LTDOT, the patient’s
COPD must be in a stable phase on optimal drug treatment.
Hypoxaemia must be confirmed by arterial blood gases
performed while the patient is breathing room air. Following
exacerbations of COPD, spirometry and PaO2 may continue to
improve for up to 3 months. Therefore in all patients these
should be checked on two occasions at least 1 month, and
preferably 3 months apart before prescribing LTDOT.
Continued smoking reduces the efficacy of treatment and is a
contraindication to oxygen therapy. Blood levels of
carboxyhaemoglobin above 3% suggest continued smoking.
Hypoxaemia is assessed with the patient at rest. Patients in
whom a fall in PaO2 occurs only during exercise and sleep do
not benefit from LTDOT.
Patients and their families need to understand both the
purpose of the treatment, and the need to use it for at least 16
hours per day. Other components of rehabilitation must be
provided.
Worsening hypercapnia caused by hypoventilation is an
occasional complication of oxygen therapy in patients with
severe COPD and hypercapnic respiratory failure. Oxygen
administration in such patients must be carefully controlled
(initial flow rates through nasal cannulae, or facemask
concentration of oxygen should be kept low until the effect on
the arterial PaCO2 confirms the absence of deterioration).
Regular follow-up by a suitably experienced physician and
ready access to technical advice, either through a private
contractor or a hospital department, must be available.
Assessment of compliance is essential.
6.4.5.2 Oxygen prescription
Oxygen is administered by facemask or nasal cannula for a
total of at least 16 hours per 24-hour day.  A flow rate of 
1 - 2 l/minute is used, the rate being determined in each case
by arterial blood gas determinations. Oximetry may be used
for follow-up checks.
Oxygen can be delivered by oxygen concentrators or by
cylinders. Concentrators are more convenient and cost
effective.
6.4.5.3 Palliative symptomatic oxygen therapy
Oxygen given for short periods to relieve breathlessness in
hypoxic patients with COPD does not influence the natural
progression of the disease and is therefore not routinely
recommended.
6.5 Prevention and treatment of exacerbations of
COPD 
6.5.1 Definition, natural history and diagnosis of
exacerbations 
An exacerbation is defined as an increase in symptoms and
signs of COPD above the usual day-to-day variation expected
by the patient. Exacerbations vary both in severity and
frequency. Most patients experience 1 or 2 episodes per year,
but some have many. They tend to become more common as
COPD progresses. Exacerbations are important clinical events
in COPD, severely affect quality of life, are associated with
permanent worsening of COPD in some patients, and account
for a large percentage of the direct costs associated with the
treatment of COPD. Their prevention is an important goal of
treatment. 
The main symptom of an exacerbation is increased
breathlessness, often accompanied by wheezing, chest tightness
and increased cough and sputum. They are often associated
with signs of airway infection, increased volume and colour
change in sputum (to yellow or green), and fever. Other
symptoms are malaise, drowsiness, insomnia, fatigue,
depression, confusion and fever. 
The most common causes of exacerbations include:
• tracheobronchial infections 
• environmental (atmospheric) pollution (including cigarette
smoke and allergen load)
• weather changes
• aspiration associated with gastro-oesophageal reflux.
The role of bacterial infection and the place of antibiotics in
the treatment of exacerbations is controversial.  Potentially
pathogenic bacteria are found in about 50% of exacerbations,
and viruses in a further proportion of episodes. In most cases
they are likely to be relevant, and reports confirm the benefit of
antibiotic treatment on the rate of recovery, morbidity, and
even hospital stay, particularly in patients with severe COPD,
and those who have severe exacerbations.
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Acute exacerbations must be distinguished from other
diseases and complications of COPD, including pneumonia,
pneumothorax, congestive heart failure, arrhythmia and
pulmonary embolism that require alternative treatment. When
exacerbations are associated with features of infection (pyrexia
and purulent sputum), the presence of pneumonia and other
forms of lower respiratory infection must be excluded using
chest X-ray. An approach to the treatment of common
tracheobronchial infections is provided in Annexure B.
6.5.2 Prevention of exacerbations 
The following measures have each been shown to reduce the
frequency and/or severity of COPD exacerbations:
• Smoking cessation
• Prevention of respiratory infections (influenza and
pneumococcal vaccination)
• Bronchodilators: regular dosing with ipratropium bromide,
theophylline, long-acting beta2-agonist, tiotropium, and in
various combinations described above
• Oral and high-dose inhaled corticosteroids alone, and in
combination with bronchodilators, particularly the long-
acting varieties.
6.5.3 Management of exacerbations 
6.5.3.1 Clinical assessment
Determine symptom changes from baseline status including:
sputum volume and character, duration and progression of
symptoms, dyspnoea severity, exercise limitation and effect on
activities of daily living. Look for evidence of respiratory
distress, bronchospasm, cor pulmonale and right ventricular
failure, pneumonia, haemodynamic instability and altered
mentation.
Investigations. Arterial blood gas or impulse oximetry (if
blood gas is not available), chest radiograph, ECG and
theophylline level (if the patient has been on theophylline).
6.5.3.2 Treatment
Bronchodilators
• First-line treatment is nebulisation with the combination of
ipratropium bromide and beta2-agonist (salbutamol or
fenoterol) given 4-hourly (or as often as every 30 - 60
minutes or continuously in severe cases).  Early conversion
to an MDI is desirable. Alternatively, multiple actuations of
an MDI delivered via a spacer device may be as effective as
nebulisation.
• Theophylline. Should there be inadequate sustained
response to the above treatment, intravenous aminophylline
may be used.
Anti-inflammatory therapy
Corticosteroids should be given, preferably orally. A once-daily
dose of 40 mg prednisone is given and continued for 10 - 14
days unless the condition fails to resolve. Tapering is not
required. An equivalent dose of an intravenous steroid may be
given if the patient is unable to take oral medication. 
Antibiotics
These should be prescribed when there is clear evidence or
strong suspicion of infection (marked sputum purulence
and/or fever), and in those with severe COPD or a severe
exacerbation. In such cases, sputum Gram stain may be of help
by confirming the presence of relevant organisms, but is not an
essential investigation. The organisms most commonly
involved are Streptococcus pneumoniae, Haemophilus influenzae
and Moraxella catarrhalis. With the increasing appearance of
resistance to penicillin and macrolides of the pneumococcus,
beta-lactam resistance of H. influenzae and M. catarrhalis, local
sensitivity data should be considered when chosing an
antibiotic. In areas where there are high levels of resistance to
the macrolides and doxycycline, these agents should be
avoided. Alternatives such as amoxycillin/clavulanate,
cefuroxime, or quinolones may be used. Intravenous
administration is preferred for severe illness and in the case of
pneumonia on chest radiograph. Duration of treatment should
be 10 - 14 days for severely ill patients or for persistent
infections.
Oxygen therapy
Oxygen should be started at 24% or 1 - 2 litres/minute by nasal
cannula.  Increases should be gradual to avoid carbon dioxide
narcosis. This should be guided by blood gas analysis or by
level of consciousness if blood gases are not available. The aim
should be to maintain the saturation above 90%.
Treatment of cardiac failure: See treatment of right heart
failure.
Heparin prophylaxis: See anticoagulant treatment.
Physiotherapy to assist with clearance of secretions. Postural
drainage and chest percussion are of limited benefit except in
patients with bronchiectasis and may cause distress. Treatment
is most useful after nebulisation with a bronchodilator.
6.5.3.3 Hospital admission
Indications for hospital admission in patients with COPD:
1. An acute exacerbation associated with one or more of the
following features:
• Sustained failure to improve on outpatient management
• Inability to walk between rooms (where previously mobile)
• Family and/or physician unable to manage the patient at
home
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• High-risk co-morbid condition, pulmonary (e.g.
pneumonia) or non-pulmonary
• Prolonged, progressive worsening of symptoms before
emergency visit
• Altered mentation
• Worsening hypoxaemia and new or worsening hypercapnia
• Newly occurring arrhythmia
• Elderly or frail patients.
2.  New or worsening right-sided cardiac failure
unresponsive to outpatient management.
Indications for ICU admission:
The usual indication is respiratory failure.  However, it is
frequently necessary to admit patients with other diseases
because they have COPD.
Pre-conditions for ICU admission:
1. Satisfactory functional status before the exacerbation
(patient coped with activities of daily living).  If not known, the
patient should be given the benefit of the doubt.
2. Possible need for mechanical ventilation, i.e.:
• PaO2 < 6.7 kPa (50 mmHg) on room air
• Arterial blood pH < 7.3
• Confusion.
3. The presence of a reversible factor.  Examples are
infections, bronchospasm, oxygen-induced carbon dioxide
narcosis, sedative administration or other associated illnesses.
Ventilatory support must be considered for patients with
one or more of the following features: 
• Hypoxaemia (PaO2 < 50mmHg) despite supplemental
oxygen
• Exhaustion, confusion, coma
• pH < 7.3 and declining (respiratory acidosis)
• Respiratory or cardiac arrest
• Inability to clear secretions.
Note: Patients with severe COPD may have chronic severe
dyspnoea, hypercapnia and  hypoxaemia that is stable and
cannot be improved. Therefore the presence of these features
must not be viewed in isolation, as an indication for ventilatory
support. Rather, ventilation is indicated for acute deteriorations
from baseline. Prior knowledge of a patient’s blood gases and
clinical status in the stable state is therefore a valuable aid.
Modalities of ventilatory support include invasive
(mechanical ventilation) and non-invasive continuous positive
airways pressure (CPAP) or BiPAP techniques.
Before discharge, the following require attention and must
be provided:
• Education on COPD (see above)
• Further need for oxygen (short-term or long-term
domiciliary oxygen — see above)
• A written home management action plan
• Outpatient follow-up appointment
• Rehabilitation plan
• A plan for smoking cessation
• Assessment of home conditions and psychosocial support.
6.6. Prevention and treatment of complications
The main complications that need to be treated include right
heart failure, severe exacerbations, pulmonary embolism,
pneumothoraces and chronic respiratory failure not related to
exacerbations.
6.6.1 Treatment of right heart failure
The management of right heart failure may be summarised as
follows: 
• Identify and treat the cause. In COPD this might include an
acute respiratory infection, worsening airflow obstruction
(review bronchodilator and other treatment) or worsening
hypoxaemia from additional factors such as a move to
higher altitude or a thrombo-embolic event.
• Administer oxygen if hypoxaemic.
• Diuretics (e.g hydrochlorothiazide 25 mg or equivalent).
Avoid large decreases in preload  which may precipitate
hypotension.
• Cardiac glycosides must be avoided except in the presence
of atrial fibrillation and/or left ventricular
dysfunction/failure. 
• ACE inhibitors and calcium antagonists are not indicated in
the management of cor pulmonale or right ventricular
failure.      
6.6.2 Anticoagulant treatment 
6.6.2.1 Heparin prophylaxis
Prophylactic subcutaneous heparin to prevent deep-vein
thrombosis in indicated during acute exacerbations where
patients are immobile for prolonged periods. 
6.6.2.2 Long-term anticoagulant treatment
Chronic treatment with warfarin needs to be considered in
patients with pulmonary hypertension and right heart failure,
in those with atrial fibrillation, and in patients with a high
haematocrit, particularly if it recurs after venesection. It should
also be considered in patients with unexplained hypoxic
episodes where pulmonary thrombosis or thrombo-embolism
is suspected. Confirmation of this diagnosis is seldom possible,
but   spiral CT scans may occasionally be diagnostic.
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6.6.3 Miscellaneous
Pneumothorax: The development of a spontaneous
pneumothorax must be considered when patients with stable
COPD suddenly deteriorate, as patients with respiratory
impairment tolerate even a small pneumothorax poorly. 
7. Additional considerations
7.1 Sleep in COPD
Sleep is associated with a decrease in arterial oxygen saturation
(SaO2) in most individuals but this trend is more marked in
COPD. Significant night-time hypoxaemia cannot be predicted
from measurement of daytime blood gas and pulmonary
function tests, but if the daytime PaO2 is ≥ 8 kPa, nocturnal
SaO2 need only be measured if unexplained respiratory failure,
cor pulmonale or erythrocytes are found.
Referral for full sleep study (polysomnography) and
specialised opinion should only be considered if sleep-
disordered breathing is suspected (i.e. daytime hyper-
somnolence and other symptoms of sleep deprivation, or a
strong history of loud snoring with apnoeic events).
Long-term domiciliary oxygen therapy, prescribed for
daytime hypoxaemia, must be used during sleep.
7.2 Surgery for emphysema
Giant bullectomy is occasionally indicated.
Lung volume reduction surgery (LVRS:  bilateral non-
anatomical excision of emphysematous lung tissue) is a useful
modality of therapy in a small, highly selected group of
patients.  These patients must be on optimal medical therapy,
severely symptomatic with dyspnoea, and have evidence of
marked air trapping and predominantly upper lobe
emphysema (confirmed by high-resolution CT scan). Careful
selection and preparation for the procedure is critical. If this is
inadequate, mortality is high and results are poor. Potential
patients must be referred to a pulmonologist participating in a
multidisciplinary LVRS programme for evaluation.  All patients
must undergo a 6-week exercise conditioning programme
before surgery.  It must be explained that the procedure is not
curative, and that any benefit is temporary and will last for
only a few years (usually 2 or 3).
7.3 COPD and surgery
Patients with COPD are at high risk during anaesthesia and
surgery.  The risk depends on the severity of the lung disease
and the nature of the proposed surgery.
All patients require pre-operative evaluation including
spirometry.  For lung resection and upper abdominal and
thoracic surgery, the minimum evaluation should include
spirometry and arterial blood gas analysis. An assessment of
exercise tolerance, either as a formal exercise test or through
scrutiny of ability to climb several flights of stairs, is a more
reliable predictor of surgical risk than FEV1, for both abdominal
and thoracic surgery. All patients with persistent dyspnoea,
(stages 2 and 3) require these investigations before surgery.
7.4 Air travel
The risks of air travel for patients with COPD include:
• Worsening hypoxaemia at altitude. Most commercial
aircraft are pressurised to an altitude of between 2 250 and
3 250 m. This altitude may have little effect on patients who
live at altitudes of 2 000 m (e.g. on the Highveld), but for
those who are hypoxaemic at sea level, this may result in
severely symptomatic hypoxaemia. Arterial PO2 decreases
by 1 - 1.5 kPa for every 1 000 m altitude. 
• Increased physical stress of travel (airport transfers,
luggage, etc).
• Risk of contracting a respiratory infection.
• Increased altitude at destination causing increased
dyspnoea.
Patients need to balance the potential discomforts and risks
against the purpose of the trip.
The need for supplemental oxygen can be predicted by
administering hypoxic air mixtures and measuring blood
gases, or by use of regression equations. However a simple
approach is recommended:
• Patients who are on LTDOT, or who are hypoxaemic at sea
level, will need supplemental oxygen on the aircraft. 
• Patients with limitation of activities of daily living should
make provision for supplemental oxygen with the airline
before the trip.
• Patients who have tolerated recent air travel well are likely
to cope with a similar trip.
• Coexistent disease, particularly ischaemic heart disease, will
make hypoxaemia more dangerous and more careful
assessment is necessary.
8. Process
In July 2001, the Council of the South African Thoracic Society
resolved to revise the 1996 COPD Guideline and appointed a
convenor and editorial committee, selected a review date and
agreed on the format of the process of revision. The working
group comprised most members of the previous working
group. The editorial committee identified areas of the guideline
requiring revision and commissioned members of the working
group to prepare reviews of new data in these areas, with
particular reference to the content of the 2001 version of the
Global Obstructive Lung Disease Guideline. The workshop
was held at Sun City, North West province, in August 2002. A
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draft revision document based on the consensus obtained at
the workshop was compiled by the editorial board and
circulated for further comment from the guideline committee,
in May 2003. These further comments were included (as
considered appropriate by the editorial committee), and the
final draft was then considered and approved by the Council of
the South African Thoracic Society by postal vote in June 2003.
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Annexure A. The Six-Minute Walk
Distance (6-MWD)
The 6-MWD provides an objective reproducible assessment of
the combined function of lung, heart and proximal muscle
endurance.  The unit of measurement is total distance covered
during 6 minutes (in metres). Level of dyspnoea during the test
may be assessed using the Borg scale (Table VII). A major use
of the test is for following the course of patients over time and
evaluating the effects of changes in treatment.
Procedure 
A 20 - 30 m indoor course is marked out with distance markers.
A treadmill may be used. The same method must be used for
subsequent follow-up tests. 
Patients must wear comfortable clothing and shoes, and take
their usual medication on the test day. Those on long-term
oxygen may perform the test with oxygen, provided that a
suitable long supply line or mobile oxygen source is provided
and carried by an assistant (not the subject). As there is a
learning effect, the first test performed by each patient should
be disregarded, and a second, performed on a different day,
regarded as the baseline value.
On arrival on the test day, the subject must rest in a chair for
10 minutes. Resting dyspnoea level, pulse, blood pressure and
oxygen saturation must be recorded.
Safety issues: Testing must be deferred in patients with a
resting pulse rate > 140 beats per minute, diastolic blood
pressure readings of  > 110 mmHg, unstable angina, or
myocardial infarction during the previous month. Monitoring
of pulse rate by means of pulse rate monitor and saturation
with a finger or ear probe is useful for determining the degree
of stress and hypoxia to which patients are subjected.
The purpose and nature of the test must be explained using
standard phrases: ‘The object of the test is for you to walk as
far as possible in 6 minutes.  Six minutes is a long time to walk,
so you will be exerting yourself.  You will probably get out of
breath and be exhausted.  You may even have to stop and rest.
You may stop and rest, but must resume walking as soon as
you are able.’ And, ‘You will walk back and forth around the
course markers.  You should pivot briskly around the markers
and continue back the other way without hesitation.’
Demonstrate how to walk and turn.
On starting the test, do not walk with the patient, but use
standard phrases of encouragement, with an even tone of
voice, each minute during the test: ‘You are doing well, you
have 5 minutes to go’. After 1 minute: ‘Keep up the good work,
you have 4 minutes to go’, etc. The patient is permitted to rest,
but the timer is not stopped. Instruct the subject to stop when 6
minutes are up, and measure the distance covered. Offer the
patient a chair, and a drink of water. If the patient stops before
the 6 minutes are up and refuses to continue (or you decide
that they should not continue) record the distance. Repeat the
Borg breathlessness scale. 
Annexure B. Terminology and
treatment of bronchial infections
The term ‘chronic bronchitis’ and its relationship to COPD and
with other forms of bronchial infections is a source of
confusion to many clinicians. The notes that follow, although
not strictly within the brief of guidelines on COPD, are offered
Table VII. Borg scale for assessing of breathlessness 
0 No breathlessness
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
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as a guide to assist clinicians to correctly assess and classify
these conditions and offer appropriate treatment.
Chronic bronchitis. Chronic bronchitis is a condition
identified on the basis of history — chronic cough with sputum
production that develops in smokers and less commonly in
persons with years of exposure to heavy atmospheric pollution.
The cough typically begins as a ‘smoker’s cough’, worse in the
morning and productive of sputum which does not appear
infected. It usually starts after a bout of winter bronchitis but
persists for months and recurs the following year under similar
circumstances. The British MRC defines chronic bronchitis as
chronic productive cough that persists for at least 3 months of
the year for 2 successive years. The pathology of the airways
includes mucosal thickening with hypertrophy of mucous
glands indicating mucus hypersecretion. Treatment is smoking
cessation, which is usually associated with partial (rarely
complete) improvement. Although chronic bronchitis is usually
associated with airflow obstruction (as in patients with COPD),
it can occur alone.
Classification of bronchitis 
The classification of bronchitis and bronchial infections is
difficult because of the plethora of terms and paucity of
distinctive features. It is, however, important to classify disease
correctly, as this serves as a guide to treatment. The following
classification is recommended for use in South Africa (Table
VIII).
• Acute bronchitis: Tracheobronchitis involving both the
trachea and upper airways and caused by viruses.
• Simple chronic bronchitis: Chronic bronchitis as defined
above, with normal or at most, mild impairment of lung
function, with bronchitis unlikely to be complicated by
respiratory failure.
• Complicated chronic bronchitis: Complications are severe
airflow obstruction (< 50% of predicted), frequent
exacerbations and/or severe respiratory limitation of
activities.
• Complicated chronic bronchitis with chronic bronchial
sepsis: Defined as infected sputum continuously or almost
continuously throughout the year. This category includes
patients with structural bronchial damage and even
bronchiectasis from any cause.
Associated risk factors, causative pathogens and
recommended antibiotic treatment are shown in Table VIII. 575
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Table VIII. Classification of bronchitis — diagnostic criteria, risk factors, usual pathogens and recommended treatment 
Diagnosis Criteria/risk factors Usual pathogens Recommended treatment*
1. Acute • Acute • Viruses • Symptomatic
bronchitis • No underlying lung disease • No antibiotic
2. Simple chronic • Symptoms define chronic • H. influenzae • Aminopenicillin
bronchitis  bronchitis • M. catarrhalis • Amoxy-clavulinic 
• Recent increase in sputum • S. pneumoniae acid 
volume and purulence • Beta-lactam • Macrolide/azalide
• FEV1 > 60% predicted resistance possible
3. Complicated • COPD with FEV1 < 60% • Same organisms as • Amoxycillin-
chronic • Advanced age in 2, but beta-lactam clavulinic acid
bronchitis • ≥ 4 exacerbations/year resistance more • Second or third
• Recent increase in sputum common generation
volume and purulence • Sputum Gram stain cephalosporin
• Significant morbidity (ill) and culture advised • New generation
fluoroquinolone
4. Complicated • As above with purulent • Same as 3, but also • Ciprofloxacin or
chronic sputum for long periods in • Enterobacteriaciae • Other quinolone
bronchitis with year • Pseudomonas • Alternative based
chronic • + X-ray evidence of aeruginosa on result of
bronchial sepsis structural lung disease • Sputum Gram stain sputum culture
and culture advised
*Selection of antibiotic is influenced by knowledge of antibiotic resistance patterns in different areas of the country.
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1. Abbreviations
ATPS = ambient temperature, ambient pressure, saturated with
water vapour; ATS = American Thoracic Society; BTPS = body
temperature, ambient pressure, saturated with water vapour;
ECSC = European Community for Steel and Coal; ERS =
European Respiratory Society; FEV1 = forced expiratory
volume in 1 second; FVC = forced vital capacity; LLN = lower
limit of normal; PEF = peak expiratory flow; RSD = residual
standard deviation; SATS = South African Thoracic Society;
TLC = total lung capacity; VC = vital capacity.
2. Introduction
Spirometry is an essential part of a complete respiratory
evaluation, but inadequate standards and variations in
standard operating procedures exist that reduce its clinical
usefulness.1 Good quality spirometry necessitates a competent
operator, accurate and reliable equipment and a co-operative
patient.  Furthermore, it involves a series of standard
procedures and quality control checks to produce technically
satisfactory results.  Finally, the results take reference standards
into account and are interpreted with consideration of the
clinical indications for testing.
Various authorities have published comprehensive
guidelines for the standardisation of spirometry.2-4 More
recently, selective South African reference standards have
become available for the normal range of forced vital capacity
(FVC) and forced expiratory volume in 1 second (FEV1). 5-10 This
statement is prompted by increased utilisation of office
spirometry in South Africa and a perceived need for simplified
guidelines for use at primary contact level, i.e. in the clinic or
practice.  Diagnostic and research lung function laboratories
will require more comprehensive guidelines than proposed in
this document.
3. Definitions
Spirometry. Spirometry is one of a number of tests to evaluate
respiratory function.  The basic spirometric procedure involves
the measurement of gas volume and rate of airflow during a
maximal, forced expiration.  The mechanical properties of the
airways, lung, pleura, chest wall and respiratory muscles all
contribute to these results.
Spirometer. Spirometers operate on one of two principles:
• Volume-type spirometers determine volume directly and
have the advantages of low cost and ease of operation.
However, data processing and storage capacity may be
limited, unless the spirometer contains a microprocessor.
• Flow-type spirometers make use of a flow-sensor
(pneumotach) to derive volumes.  They are computerised,
provide quick reference values, produce flow-volume loops
enabling instant pattern recognition and can usually store
Guideline for Office Spirometry in Adults, 2004
South African Thoracic Society Standards of Spirometry Committee: E M van Schalkwyk, C Schultz, J R Joubert, N W White
Objective. To provide clinical guidelines for office spirometry
in South Africa.  
Options. More stringent guidelines are required for diagnostic
laboratories and research.
Outcomes. To minimise variations in standard practice and
improve the quality and usefulness of spirometry in the
clinical setting.
Evidence. Recommendations are based on key international
publications as well as research publications regarding
reference values for South Africans.
Benefits, harm and costs. The medical, social and economic
benefits and costs of standardisation of office spirometry in
South Africa were considered in the recommendations.
Validation. The document has been reviewed and endorsed by
the South African Thoracic Society.
Conclusions. The indications for spirometry must be specific
and clear.  Spirometry equipment must meet internationally
accepted performance standards and carry proof of
validation.  Equipment must be regularly calibrated and
maintained.  Individuals performing spirometry must be
adequately trained and demonstrate a high level of
competence.  Subject preparation, testing and quality control
of results must be carried out according to published
guidelines.  Finally, test results must be interpreted according
to current diagnostic guidelines, taking into account the
purpose of the test, appropriateness of reference values and
the clinical evaluation.
S Afr Med J 2004; 94: 576-587.
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large data sets.  On the other hand, they require greater
expertise to operate, calibrate and maintain.
Spirogram. Spirograms are the graphic displays produced by
spirometers.  In addition to graphs, they provide the measured
values (observed), the reference values (predicted) and the
measured values expressed as a percentage of the reference
values (% predicted).  Volume-type devices generate volume-
time curves (Fig. 1a) and flow-type devices generate flow-
volume curves (Fig. 1b).  Newer flow-type spirometers can
produce both types of curve.
Measurements.  Depending on type and level of
sophistication, spirometers can produce a range of measurements
that may assist in the clinical interpretation of results:
• Vital capacity (VC): VC is the total volume of gas inhaled from
the position of maximal expiration or exhaled from the
position of maximal inspiration.  It is measured with a
relaxed/slow breathing manoeuvre either during inspiration
or expiration.  VC is expressed in litres (BTPS).  BTPS refers to
a standardised volume at normal body temperature (37°C) at
ambient pressure, saturated with water vapour.
• Forced vital capacity (FVC): FVC is the maximum volume of
gas exhaled from the position of maximal inspiration by
means of a rapid, maximally forced expiratory effort,
expressed in litres (BTPS). 
• Forced expiratory volume in 1 second (FEV1): FEV1 is the volume
of gas exhaled during the first second of the FVC manoeuvre,
expressed in litres (BTPS).
• FEV1/FVC%: FEV1/FVC% is observed FEV1 expressed as per
cent of observed FVC (FEV1/FVC × 100).
• Peak expiratory flow (PEF): PEF is the maximum flow
generated with a FVC manoeuvre, expressed in litres per
second (BTPS).
Measurements of FVC, FEV1 and FEV1/FVC% are the
minimum required for diagnostic interpretation of results.  VC
measurements are useful for evaluating dynamic collapse of
small airways as found in emphysema.
Calibration.  Calibration is the process whereby the accuracy
(truthfulness) and precision (repeatability) of a device such as a
spirometer are tested and corrected using a gold standard such
as a calibration syringe with a standard volume.
Validation.  Validation is the process of establishing and
certifying the accuracy and precision of a device.
Operator. The term operator refers to the person performing
spirometry. 
4. Indications for spirometry
Specific and clear indications for spirometry are helpful in the
interpretation of results.  The most frequent clinical indications
for spirometry are listed below:
• To confirm a diagnosis in:
• Individuals with suspected obstructive or 
restrictive lung disease. 
• To grade respiratory impairment in.
• Medico-legal cases (e.g. assurance or disability)
• Individuals on treatment action plans (e.g. COPD)
• Individuals for lung resection, and individuals for 
thoracotomy or upper-abdominal surgery if they 
have chronic respiratory diseases. 
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Fig. 1.  (a) Volume-time, and (b) flow-volume curves.  In the flow-type
spirometer FEV1 is a derived value.  It can only be read from the flow-
volume graph if a 1-second timer is displayed.
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• To monitor changes in lung function in:
• Individuals with chronic respiratory diseases — to 
evaluate responses to treatment and disease 
progression.
• Workers regularly exposed to substances known to cause
respiratory diseases.11
• To screen for lung disease in:
• Smokers  
• Individuals with persistent respiratory symptoms, 
including shortness of breath (dyspnoea), chest 
tightness, wheezing, coughing, sputum production and
chest pain.
• New employees with potential for exposure to 
substances known to cause respiratory diseases — 
to determine baseline lung function. 
• Workers with significant exposure to substances 
known to cause respiratory diseases.
Spirometry is frequently applied in the occupational
environment for surveillance purposes.  Its sensitivity and
specificity for detecting early disease varies and a screening
programme should be tapered to the specific needs of the
workplace.  For example, early changes of COPD or asbestosis
are detectable with spirometry, whereas early changes of
silicosis are better detected with chest radiography.  For
occupational asthma, because of its varying nature, a
respiratory symptoms questionnaire is frequently combined
with spirometry in screening or surveillance programmes.
5. Specifications for spirometers
5.1 Proof of validation
Spirometers may lack accuracy and precision.  Prospective
purchasers of equipment should seek its proof of validation.
Accuracy depends on the resolution (minimal detectable
volume or flow) and linearity (consistency) of the entire system
from the measuring components to the recording and display
components.  The American Thoracic Society (ATS) has
published minimal performance criteria for diagnostic and
monitoring spirometers and guidelines for validating
equipment using waveform-generated calibration syringes.2
Selective ATS recommendations for diagnostic spirometers are
provided in Tables I and II.  Table II provides standards for
graph output.  Manufacturers should follow these guidelines to
ensure that spirometers provide accurate data that are
comparable between different settings and over time.
Commercially available devices for monitoring of FEV1 and PEF
have disadvantages for office spirometry because they may be
less accurate, usually cannot be calibrated to ensure their
performance, and graphical displays may be absent or
inadequate for evaluation of test quality.  
Other recommendations include:
• The  BTPS-correction facility that meets ATS standards:  The
volume of exhaled gas is measured outside the body at
ambient conditions, designated ATPS (ambient temperature,
ambient pressure, saturated with water vapour).  These gas
measurements are corrected to reflect conditions inside the
lung (BTPS).  Without this facility, mathematical correction
of volumes has to be done manually.2
Table I.  Selective minimum volume and flow criteria for diagnostic spirometers 
Parameter Required range Accuracy (BTPS) Flow range (l/s) Time (s) Validation method 
VC 0.5 - 8 l ± 3% of reading or ± 0  - 14 30 3 l calibrated syringe
0.050 l, whichever 
is greater
FVC 0.5 - 8 l ± 3% of reading or ± 0  - 14 15 24 standard waveforms/
0.050 l, whichever 3 l calibrated syringe
is greater
FEV1 0.5 - 8 l ± 3% of reading or ± 0  - 14 1 24 standard waveforms
0.050 l, whichever 
is greater
PEF ± 10% of reading or 0  - 14 26 flow standard
± 0.400 l/s, whichever waveforms
is greater
Precision: ± 5% of
reading or ± 0.200 
l/s, whichever is greater
Table II.  Minimum scale factors for spirograms*
Parameter Required resolution Scaling
Volume 0.025 l 10 mm/l
Flow 0.1 l/s 5 mm/l/s
Time 0.2 s 2 cm/s
*For the flow-volume curve exhaled flow is plotted upwards and exhaled volume
towards the right in a 2:1 ratio.
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• Facility to generate real-time spirograms — to enhance
feedback and subject compliance.
• Stated source(s) of reference values and facility to select or
enter appropriate values manually.  
• Computer-driven technical quality indicators that meet ATS
standards (computer automatically evaluates test quality
based on pre-programmed criteria and gives prompts).  
• Printing facility for record-keeping purposes.
• Adequate facility to save large numbers of tests and test
quality indicators where needed, for example, for
occupational surveillance.
• Availability of after-sales service.
In addition to mechanical validation, spirometers can also
be tested in real-life situations involving human subjects.12
SATS recommend that independent professional advice
from a registered pulmonology training laboratory or the
Spirometry Training and Certification Committee of the South
African Thoracic Society (SATS) be obtained before a new
spirometer is acquired.
5.2 Calibration 
All diagnostic spirometers must be volume-calibrated at least
daily using a calibrated syringe with a volume of at least 3 l to
ensure that they remain accurate during use.  During industrial
surveys in which a large number of subject manoeuvres are
performed, calibration must be checked each morning and at
least twice during the day.  In circumstances where the
temperature may change markedly over the day, for example
in field surveys, more frequent temperature corrections are
necessary.  
Calibration involves the following steps:
1. The spirometer is switched to calibration mode (to
prevent BTPS-correction because room air is injected).  Room
temperature and barometric pressure readings are entered.  In
the absence of a barometer, barometric pressure readings can
be obtained from the local airport or weather bureau. 
2. Calibration syringe size is specified.  A 3 l syringe is
recommended.  Currently, the use of 2 l and 1 l syringes is not
validated.
3. The calibration syringe is connected to the spirometer and
the maximum volume of air injected.  Flow-type spirometers
are calibrated by injection of the maximum volume from the
syringe at least three times, each time at a different speed, to
cover a range of flow rates.  Calibration is complete when the
recorded volumes are within 3% or 50 ml, whichever is the
greater, for each flow rate tested.  In the event of in-line
(antimicrobial) filters being used, calibration should be done
with a filter installed.  The quality of the filter must be such
that the spirometry system still meets ATS standards.
4. Volume-type spirometers are checked for air leaks if the
measured volume remains outside the acceptable range.  A leak
can be detected by applying a slight constant positive pressure
with the calibration syringe while the spirometer outlet is
occluded.  Any volume change greater than 10 ml after 1 minute
indicates a leak.  Faults are corrected and calibration repeated.  
5. Remaining problems are logged and referred to the
manufacturer without delay.  
The use of biological standards such as, for example, the
operator for daily volume calibration (biological calibration)
cannot replace the use of a calibration syringe.  Lung function
testing involves a ‘system’ consisting of three main
components: spirometer, operator and test subject.  Each of
these can be a source of variation in measurements and syringe
calibration is required in order to isolate the device. Biological
standards are useful for testing software irregularities such as,
for example, inconsistencies in the calculation of predicted
values.  Also, when they are used in conjunction with a
physical standard (calibration syringe), biological standards are
useful to test the proficiency of operators.
In addition to daily volume calibration, spirometers must be
maintained routinely according to the manufacturer’s
specifications.  This includes the cleaning of pneumotachs at
least once a week (more frequently if there is visible
condensation), as they are particularly sensitive to moisture
and secretions.  Other components of the spirometer, for
example the time clock, must also be calibrated from time to
time.  For these and other maintenance functions the
manufacturer must routinely check spirometers at least 6 - 12-
monthly. 
6. Responsibilities of operators
6.1  Skills
Operators must have an understanding of the principles
underlying the measurement and equipment operation.  They
must also be able to ensure optimal subject co-operation,
provide acceptable, reproducible results and recognise common
abnormalities. Training of pulmonary medical technologists
includes this competency and competency to perform
advanced lung function tests and laboratory quality assurance.
The SATS is in the process of developing a curriculum, training
materials and a means of certification of proficiency in
performing spirometry for people other than pulmonary
medical technologists.   
6.2  Quality assurance
A quality assurance programme is critical to ensure a well-
functioning spirometry laboratory.13 This may be difficult to
attain in a routine clinical practice.  At a minimum, a
calibration and maintenance log as well as electronic or hard
copies of whole spirograms must be kept so that accuracy and
precision of past tests can be verified.  Additionally, standard
operating procedures should be documented and kept for
reference purposes.
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6.3 Infection control
Various components of the spirometry system, including
mouthpieces, nose clips, pneumotachs, valves and tubing, are
potential vehicles for transmission of infection to subjects and
staff.  Transmission of upper respiratory tract infections, enteric
infections and blood-borne infections such as hepatitis and
HIV, can potentially occur through direct contact when test
subjects have open sores in the mouth, bleeding gums or
haemoptysis.  Tuberculosis and viral and nosocomial infections
can also occur, indirectly, through inhalation of aerosol droplets
from the spirometer or surroundings.  The type of test
manoeuvre determines whether inhalation from the spirometer
takes place.  This has a major influence on the extent of
infection control needed.  An expiratory manoeuvre without
inhalation from the spirometer reduces the potential for cross-
infection dramatically and is the method of choice for mass
screening purposes.  
Infection control recommendations for expiratory
manoeuvres without inhalation from the spirometer:
• Spirometry should be performed in a well-lit and ventilated
area.
• Hands must be washed immediately after direct handling of
mouthpieces or other potentially contaminated spirometer
parts, and between subjects, to avoid operator exposure and
cross-contamination.  Gloves should be worn for personal
protection if there are open cuts or sores on the operator’s
hands.  
• A clean disposable mouthpiece or a disinfected re-usable
mouthpiece must be used for every test subject.  Any other
spirometer part coming into direct contact with mucosal
surfaces must be decontaminated/sterilised.
• Spirometers must be cleaned regularly according to the
manufacturer’s recommendations and the frequency of tests
done.  Any part with visible condensation from expired air
must also be decontaminated before re-use.
Additional infection control recommendations for
manoeuvres involving inhalation from the spirometer system
or part of the system:
• In-line filters must be used and replaced after each subject,
or
• Involved parts of the system (i.e. spirometer, breathing
tubes and resistive element of the pneumotach) must be
decontaminated/sterilised/flushed after each subject.
(Note: re-calibration is necessary every time a system has
been dismantled for decontamination.) 
Special precautions for patients with haemoptysis or
known transmissible infections such as tuberculosis:
• In-line filters must be used routinely (even if expiratory
manoeuvres are performed exclusively) with sterilisation of
contaminated surfaces only, or 
• Equipment must be decontaminated/sterilised/flushed
completely after each case.  Testing such cases at the end of
the day will allow for overnight decontamination of
equipment.  (Note: indications for spirometry in known
active tuberculosis are limited.)
For decontamination/sterilisation procedures, consult the
user manual or contact the infection control unit or lung
function laboratory at an academic hospital near you.
7. Preparation of subjects
7.1 Exclusion criteria
The main exclusion criterion for spirometry in routine clinical
practice is current respiratory infections in individuals for
impairment/disability assessment.  Respiratory infections can
cause temporary lung function impairment and spirometry, if
required, should be done only once infections, including
tuberculosis, have resolved.  
7.2 Personal information
The following information is required for reference purposes
(section 9.2) and must be entered into the programme: weight
and standing height, age, sex and race.  For height and weight
measurements the subject should be barefoot and wear only
light clothing.  It is also useful for interpretation purposes to
record the time of last bronchodilator use and smoking status.
7.3 Positioning and preparation
The subject must be made to feel comfortable.  Shelter him/her
from other subjects to minimise inhibitions or distractions.
Loosen tight clothing.  Leave well-fitting dentures in, but
remove loose-fitting ones.  Test the subject sitting upright on a
firm chair with his/her chin slightly elevated and neck slightly
extended.  This posture should be maintained during the
forced expiration.  Discourage excessive bending at the waist.
Use of a nose clip is strongly recommended.  Instruct the
patient when to insert the mouthpiece, for example, at the end
of maximal inspiration.  Ensure that the subject does not bite
the mouthpiece too hard, that the lips are sealed tightly around
it, and that the tongue does not obstruct the mouthpiece in any
way.
Ensure maximum subject co-operation.  Submaximal efforts
are a frequent cause of abnormal results.  Explain techniques in
simple terms and demonstrate them to the patient.  For
example, explain that: ‘I am going to have you blow into the
machine to see how big your lungs are and how fast the air
comes out.  It does not hurt but requires your co-operation and
lots of effort.’  Explain and demonstrate the use of a nose clip
and mouthpiece.  Remind the patient of a few key points.  ‘Be
sure to take as deep a breath as possible, blast out hard and do
not stop blowing until I tell you to do so.’  Give feedback about
the performance, encourage and describe what improvements
can be made.
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8. Execution of tests
8.1 Test manoeuvres
Test manoeuvres are determined in part by the setting and
level of sophistication of the spirometer:
• Expiratory-only method. For reasons of ease, cost and
infection control this method is recommended for mass
screening.  It consists of a FVC test with or without a slow
VC test.  For the FVC test, the test subject is required to
inhale maximally before inserting the mouthpiece and
starting the test.  Expiration must be rapid, forceful and
complete, lasting at least 6 seconds.  If significant
obstruction is demonstrated, proceed with a slow VC test.
The slow VC test is preceded by a maximal inspiration, the
mouthpiece is inserted and the patient then breathes out in
a relaxed fashion and for as long as possible.  Allow for up
to 15 seconds.  Only the VC is recorded.  The rationale for
performing a slow VC test is as follows: the slow VC provides
additional information on the characteristics of the obstructive
defect.  A reduction in FVC compared with slow VC suggests
dynamic collapse of unsupported airways during forced expiration
leading to air trapping.  This pattern is typically seen in
emphysema. 
• Inspiratory-expiratory method. With this method both
inspiration and expiration are recorded to generate a flow-
volume curve on a flow-type spirometer.  Typically, after
insertion of the mouthpiece, a period of quiet breathing is
followed by a complete expiration, a rapid, forceful and
complete inspiration and finally, a rapid, forceful and
complete expiration.  Some programmes prompt for an
expiratory manoeuvre followed by an inspiratory
manoeuvre.  However, the first method is recommended,
because this will reveal air trapping as described in the
previous section.  Reduced FVC compared with forced,
inspiratory VC is suggestive of air trapping.  
8.2 Test quality
The final step in ensuring data quality is the evaluation of
spirograms for acceptability and reproducibility.
8.2.1 Acceptability 
A technically acceptable FVC trial (Fig. 1) must exhibit the
following qualities:
• A ‘crisp’, unhesitating start.
• PEF of the flow-volume curve achieved within the first 25%
of the volume expired from maximum inspiration.  (Most
individuals are able to produce PEF within the first 15% of
the volume expired.)
• A continuous smooth exhalation without artefacts caused
by coughing, variable effort, second inhalations or leaks
influencing FEV1 or FVC.
• A complete exhalation (to the point where no more air can
be expelled from the lungs), lasting until the volume-time
curve has clearly reached a plateau or the flow-volume
curve has progressively returned to zero flow.  
All technically unsatisfactory trials must be rejected.
Common patterns are illustrated in Figs. 2 - 4.  
8.2.2 Reproducibility 
Suboptimal effort by the test subject is a frequent cause of
diminished lung function results.  Ensuring reproducibility of
test results is a way of verifying that the test subject co-
operates fully and provides  maximal effort.  Reproducibility is
defined as two curves in which the difference in FVC and
FEV1, respectively, do not exceed 0.2 l.  Reproducibility is
usually evident from the spirogram at a glance (Fig. 5).  Testing
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Fig. 2.  (a) Volume-time, and (b) flow-volume curves exhibiting
cough artefacts (X) that can influence observed FVC and FEV1.
Volume-time graphs are better for evaluating end-of-test quality. 
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must continue until a minimum of three technically acceptable
FVC trials have been obtained, at least two of which are
reproducible.  However, no more than eight trials should be
performed during a single session, because fatigue induced by
repeated FVC trials can lead to reduced results.  Subjects with
asthma sometimes demonstrate spirometry-induced
bronchoconstriction leading to a progressive reduction in lung
function with successive trials.  This finding will be of interest
to the clinician and all acceptable curves should be kept for
reporting.  Failure to obtain reproducibility after eight trials
must be documented, but selection of the best curve may
proceed.  
9. Interpretation of results
9.1 Selection of the best test
For diagnostic purposes, the best spirogram must be inspected,
i. e. the graph with the largest sum of FVC and FEV1.  For
impairment or severity grading the highest values recorded for
FVC and FEV1 must be selected from all acceptable curves,
including the post bronchodilator curves, even if they come
from separate curves.  
9.2 Reference standards
An individual’s observed results are evaluated for
abnormalities against predicted results derived from a normal
Fig. 3.  (a) Volume-time, and (b) flow-volume curves exhibiting
glottis closure (X) resulting in premature termination of effort and
reduced observed FVC.
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Fig. 4.  (a) Volume-time curve exhibiting a slow rise and the end-of-
test not reaching a plateau, and (b) flow-volume curve with a late
peak flow and an abrupt end-of-test.  Failure to demonstrate
reproducibility will confirm these as submaximal efforts.
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reference population.  The comparison is made as per cent
observed/predicted.  Predicted values for FVC and FEV1 are
calculated from equations based on age, height and gender
because these characteristics are the most important
determinants of lung and airway size in healthy individuals.14-17
Office spirometers are typically programmed with prediction
equations derived from the study of Caucasians, such as the
European Community for Steel and Coal (ECSC) (Table III).17
Caucasians, when compared with indigenous populations,
usually show higher FVC and FEV1, but similar or lower
FEV1/FVC%.  The use of inappropriate predicted values can
result in an increased rate of abnormal results in clinically
normal people.
The use of prediction equations based on studies carried out
in South Africa, has been investigated.18 Indigenous equations,
as detailed in Table IV, are, where available, recommended for
population screening, surveillance and medico-legal purposes.
However, it is acknowledged that the application of these
predicted values in every context where spirometry is used
may present practical difficulties.  Alternatively, office
spirometers usually have a facility for application of a
correction factor such as 0.9 for adjusting predicted values for
Caucasians with a view to their being used for indigenous
populations.  Adjusted per cent predicted can be calculated
using the formula: 
[Observed indigenous /(predicted Caucasian × 0.9)] × 100]
While the use of such correction factors is acceptable, when
understood as an approximation, use of the recommended
prediction equations is the preferred option.  Operators must
familiarise themselves with their spirometers regarding these
conditions.              
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Table III.  ECSC prediction equations* from Quanjer et al.17
Parameter Prediction equation 1.64 × RSD
Men
FEV1
† (l) 4.30H – 0.029A – 2.49 0.84
FVC† (l) 5.76H – 0.026A – 4.34 1.00
FEV1/VC% – 0.18A + 87.21 11.8
Women
FEV1
† (l) 3.95H – 0.025A – 2.60 0.62
FVC† (l) 4.43H – 0.026A – 2.89 0.71
FEV1/FVC% – 0.19A + 89.10 10.7
*Valid for age 18 - 70 years. Between age 18 and 25 years substitute age 25 in the
equation.  The lower limit of normal (LLN) is the lower 5th percentile: predicted
value – 1.64 × RSD. 
†80% predicted is an accepted alternative LLN.
H = standing height (m); A = age (years); RSD = residual standard deviation.
Table IV.  Prediction equations* from Louw et al.5 (African men)
and Mokoetle et al.8 (African women)
Parameter Prediction equation 1.64 × RSD
Men
FEV1 (l) 2.9H – 0.027A – 0.54 0.75
FVC (l) 4.8H – 0.024A – 3.08 0.89
Women
FEV1 (l) 3.4H – 0.028A – 1.87 0.64
FVC (l) 4.5H – 0.023A – 3.04 0.67
*The lower limit of normal (LLN) is the lower 5th percentile: predicted value – 1.64 ×
RSD. 80% is an acceptable alternative LLN.
H= standing height (m); A = age (years); RSD = residual standard deviation.  
Fig. 5. (a) Volume-time, and (b) flow-volume curves each
demonstrating three acceptable FVC trials, only #2 and #3 of which
are reproducible.
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9.3 Diagnosis and severity grade
9.3.1 Algorithm
The major aims of interpreting spirometric results are to
confirm the clinical diagnosis and to estimate the severity of
the disease.  An algorithm is presented (Fig. 6) for categorising
spirometric results as obstructive, normal or restrictive
patterns.  The algorithm employs three variables, namely
FEV1/FVC%, % predicted FVC and % predicted FEV1.  The
interpretative strategy proposed is based on published
guidelines,19 but the lower limit of normal (LLN) for
FEV1/FVC% has been adapted to conform to current diagnostic
guidelines for chronic obstructive pulmonary disease (COPD).20
The LLN for FEV1/FVC%, FVC and FEV1, is the 5th
percentile (see Tables III and IV). Eighty per cent predicted is
an acceptable alternative LLN for FVC and FEV1. The use of a
fixed percentage for the LLN for FEV1/FVC% (usually 70% or
75%) is a pragmatic clinical approach, but has limitations. For
screening purposes it may be more accurate to use the 5th
percentile to minimise misclassifications of borderline values. A
reduced FEV1 should always be regarded as abnormal. When
this is the only finding on the spirogram, further investigations,
including a bronchodilator test, may be necessary to define the
abnormality (see Fig. 6).
Non-clinicians such as, for example, occupational health
nurses can use the algorithm to identify cases for referral.  The
experienced clinician will use this information in combination
with pre-test information, including the indications for testing,
and his/her knowledge about the case to make a final clinical
diagnosis. 
Fig. 6.  An algorithm for categorising spirometric results is
presented.  The observed FEV1/FVC is expressed as a percentage and
the lower limit of normal (LLN) is defined as 70%.  FVC and FEV1
are based on per cent predicted (%pred) and LLN defined as 80%
(BD = bronchodilator).
Is the test acceptable? Yes
Is the test reproductible? Yes
Are the reference values appropriate? Yes
FEV1/FVC% < 70%:
OBSTRUCTIVE
(% pred FVC < 80%:
OBSTRUCTIVE with reduced VC)
FEV1/FVC% =  or > 70%:
NON-OBSTRUCTIVE
Perform BD-test %pred FVC < 80%
RESTRICTIVE
%pred FVC =  or > 80%:
NORMAL
(Except when %pred FEV1 < 80%:
further tests indicated, including BD test)
Grade impairment Grade impairment
Fig. 7.  Flow-volume curves exhibiting typical (a) reversible
obstruction in an asthmatic, and (b) non-reversible obstruction in a
person with COPD (black = pre-bronchodilator, grey = post-
bronchodilator, broken line = reference standard).
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9.3.2 Obstructive defect
An obstructive ventilatory defect is defined as a
disproportionate reduction in maximal airflow from the lung
with respect to the maximal volume that can be displaced from
the lung.  The experienced clinician will readily recognise a
pattern of expiratory airflow limitation on the flow-volume
curve (Fig. 7).  The diagnosis of an obstructive defect should be
followed up with a bronchodilator test to examine the nature of
the obstruction.  Severity of obstruction is graded according to
the worst affected spirometric parameter, usually % predicted
FEV1.  Mild obstructive defects could be missed if there is
under-estimation of FVC due to unacceptable end-of-test
criteria.
9.3.3 Restrictive defect
A restrictive ventilatory defect is characterised physiologically
by a reduction in total lung capacity (TLC) as determined by
advanced lung function testing.  One may infer a restrictive
defect when FEV1/FVC% is normal or high (non-obstructive)
and FVC is reduced (Fig. 8).  The severity of the restrictive
defect is graded according to TLC when available, otherwise it
is graded according to the worst affected spirometric
parameter, and usually % predicted FVC.
A range of conditions can reduce FVC per se:
• Conditions impeding movement of the chest wall (e.g. pain,
pleural thickening or effusion, neuromuscular weakness,
skeletal abnormality or hyperinflation with air trapping as
found in COPD).
• Diffuse conditions of lung parenchyma causing stiffness of
the lung (e.g. interstitial lung disease with fibrosis,
pulmonary oedema).
• Conditions causing reduced communicating lung volume
(e.g. lung resection, occlusion of a main bronchus, post-
tuberculous lung destruction and space-occupying lesions
in the chest). 
Restrictive abnormalities are often over-diagnosed because
of poor effort by the patient (Figs 3 and 4) or the use of
inappropriate prediction equations.  Nevertheless, diagnostic
interpretation of a reduced FVC can be difficult and referral to
a specialist must be considered after exclusion of obvious
technical causes.  
9.3.4 Obstruction with reduced FVC
This pattern consists of reduced FEV1/FVC% and FVC and is
usually found in obstructive conditions such as, for example,
severe emphysema or asthma, but a combination of an
obstructive and restrictive condition can produce a similar
result.  Other VC manoeuvres (section 8.1) and a
bronchodilator test (Fig. 7), performed in the office, can assist
in further defining the underlying disease.  The severity of the
defect is graded according to the indicator showing the most
severe defect, usually % predicted FEV1.
9.3.5 Bronchodilator response
The purpose of a bronchodilator test is to determine whether
airway obstruction, as measured by spirometry, is reversible
with inhaled beta-2 agonists (Fig. 7).  A bronchodilator test can
be standardised as follows:
1. Two reproducible FVC trials are obtained from the test
subject.
2. Two puffs (400 µg) of salbutamol or equivalent are
administered.
3. A waiting period of at least 10 minutes is introduced.
4. Two reproducible FVC trials are again obtained.
5. The best post-bronchodilator FEV1 is evaluated for a
significant improvement of at least 200 ml and 12% from the
best pre-bronchodilator FEV1.  Per cent improvement in FEV1
can be calculated using the formula: 
[FEV1 pre-BD - FEV1 post-BD/ FEV1 pre-BD] × 100
The post-bronchodilator FVC trials must be done at least 10
minutes after administration of the bronchodilator, but ideally
only after 20 - 30 minutes, as this is the time of maximum effect
of most short-acting bronchodilators.  Both the pre- and post-
bronchodilator FEV1 must be reproducible; otherwise a
response cannot be confidently interpreted as such.  For an
accurate interpretation of a negative response, subjects must
have been weaned from short-acting bronchodilators for at
least 4 hours and long-acting bronchodilators and theophylline
for at least 12 hours, if medically possible.  A number of
factors, including the dose of bronchodilator, recent prior
bronchodilator medication and timing of the post-
bronchodilator FVC trials can influence the magnitude of the
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Fig. 8.  Flow-volume curve exhibiting a typical restrictive pattern in
a person with sarcoidosis (broken line = reference curve).  The
‘shoulder’ on the down-slope of the expiratory curve was reproducible
(not demonstrated).  It represents a normal physiological
phenomenon of the expiratory curve.
586
July 2004, Vol. 94, No. 7  SAMJ
ORIGINAL ARTICLES
response significantly.  Each practice should decide on a
standard protocol.
9.3.6 Grading respiratory disease severity 
The main indications for grading respiratory disease severity
are to quantify respiratory impairment/disability for medico-
legal purposes, and to optimise and standardise treatment
practices.
Guidelines for grading spirometric impairment correlate
different lung function tests, including spirometry, with the
ability to perform physical activities.21 For this purpose criteria
for spirometry, performed in the office, are included (Table V)
for use in conjunction with the algorithm. LLN for FEV1/FVC%
has been adapted to conform to current diagnostic guidelines
for chronic obstructive pulmonary disease (COPD).20 A
severity grade is awarded according to the worst affected
parameter. The grading of obstruction should be based on the
post-bronchodilator values.
In most cases simple spirometry will be sufficient for
evaluating respiratory impairment.  However, if discordance is
found between spirometry and the stated level of dyspnoea or
clinical evaluation, additional lung function tests may be
indicated and the subject must be referred to a specialist with
diagnostic lung function facilities.  Further tests might include
carbon monoxide diffusing capacity (DLCO) and/or exercise
testing.  In addition to spirometry, DLCO is clinically one of the
most useful tests of lung function.  It is especially useful in
interstitial lung diseases, including the pneumoconioses, where
gas transfer at alveolar level might be affected
disproportionately to the mechanical properties of the lung.
Another factor that needs to be considered during the clinical
evaluation is the potential contribution of extra-pulmonary
disease, for example, ischaemic heart disease, to total
impairment.  Also, because of its varying nature, the usual
spirometric criteria do not apply to asthma as far as assessment
of impairment/disability is concerned.22
As stated before, treatment guidelines also use spirometric
grading to standardise treatment practices.  These guidelines
for grading severity are usually disease-specific and their main
aims are to control the disease and improve prognosis.
Therefore, the spirometric grading could differ from general
guidelines aimed primarily at quantifying functional
impairment.
9.4 Reporting
Spirometry reports must contain the following information:
• Identification of subject and date of testing.
• Personal  information (see section 7.2) and origin of
reference values.
• Numerical values and graphs to assess acceptability and
reproducibility (at least two curves, but preferably three).
• Latest calibration date.
The report should refer to lung function and not disease
(e.g. ‘obstructive lung function defect without reversibility’
rather than ‘chronic obstructive lung disease’), unless the
reporter is a clinician and has full clinical details to make an
appropriate diagnosis. 
10. Spirometry Training and
Certification Committee
For further information on training opportunities, readers may
contact the Chair, Spirometry and Training Certification
Committee, South African Thoracic Society, PO Box 16433,
Vlaeberg, 8018.
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